Ibrutinib

Active Ingredient: Ibrutinib
Form: Capsule
Brand Name: Imbruvica
Generic Name: Brutini
Generic Manufacturer: Ziska Pharmaceuticals

Indications:
Imbruvica is indicated for the treatment of mantle cell lymphoma (MCL) after at least one prior therapy, chronic lymphocytic leukemia (CLL) including patients with 17p deletion, Waldenström’s macroglobulinemia (WM), and marginal zone lymphoma (MZL).

Dosage and Administration:
The recommended dose is 560 mg once daily for MCL and MZL, or 420 mg once daily for CLL and WM. Capsules should be swallowed whole, not chewed, and taken continuously as prescribed until disease progression or intolerable toxicity.

Common Side Effects:
Bleeding, infections, cytopenia, atrial fibrillation, hypertension, and gastrointestinal issues such as diarrhea and visual disturbances.

Storage:
Store below 30°C in a cool, dry place away from light. Keep out of reach of children.

Frequently Asked Questions

Q: What is the relationship between Imbruvica and Ibrutinib?
A: Imbruvica is the brand name registered by the original manufacturer. Ibrutinib is the name of its active ingredient.

Q: Is the Imbruvica sold by Mediva Rx the original brand-name drug?
A: No. Mediva Rx offers a high-quality generic version produced by one of Bangladesh’s top 10 pharmaceutical companies. It contains the same active ingredient and efficacy as the original drug, tested and approved by the Directorate General of Drug Administration (DGDA).

Q: Is the manufacturer of this generic version reliable?
A: Yes. Ziska Pharmaceuticals is a leading pharmaceutical company in Bangladesh with certified R&D, production, and quality control facilities. They meet international pharmaceutical manufacturing standards, so you can buy with confidence.

Disclaimer:
This information is for reference only. Please follow your doctor’s instructions and consult the medication guide and latest clinical research when making treatment decisions.

Drug Instructions (Package Insert):
Download Link